Stephan Winckels (MD, PhD) Stephan Winckels, MD, PhD
Chief Medical Officer (Interim)

Stephan Winckels (MD, PhD) has over 10 years of oncology experience. After his training as Medical Doctor in 2002, Stephan obtained his PhD in Medical Physiology in 2007. From 2008 onwards Stephan decided to dedicate his career to oncology and started as a resident in pathology at University Medical Center Utrecht. In 2009, Stephan joined the pharmaceutical industry subsequently at Wyeth (now Pfizer), Boehringer Ingelheim, and the CRO Julius Clinical in which he fulfilled roles as medical monitor, project manager, protocol author, safety physician, proposal writer and medical lead, focusing on phase I-III oncology studies. Stephan started at CATO SMS (back then still SMS-oncology) in February 2016 as Director Medical Affairs, and joined the management team in Amsterdam as Chief Medical Officer in May 2019. In 2020, Stephan became Therapeutic Area Lead Oncology at CATO SMS. Through CATO SMS, Stephan started as interim CMO for Glycostem in October 2020. At Glycostem, Stephan is responsible for medical oversight of oNKord®